Welcome to our dedicated page for Adaptive Biotechnologies Corporation news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies Corporation stock.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) is a commercial-stage biotechnology company dedicated to leveraging the intricate biology of the adaptive immune system to innovate in the diagnosis and treatment of diseases. The company's proprietary immune medicine platform combines high-throughput sequencing with cutting-edge computational infrastructure to offer detailed analyses of T- and B-cell repertoires, critical elements in the body's immune response. Adaptive focuses on two primary business areas: Minimal Residual Disease (MRD) and Immune Medicine.
One of Adaptive's flagship products is clonoSEQ®, a highly sensitive and standardized test authorized by the FDA for detecting minimal residual disease (MRD) in patients with multiple myeloma (MM), B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL). The clonoSEQ test is also available as a CLIA-validated laboratory developed test (LDT) for other lymphoid cancers, such as diffuse large B-cell lymphoma (DLBCL). The MRD status measured by clonoSEQ serves as a powerful predictor of patient outcomes, aiding in personalized treatment and monitoring strategies.
Adaptive Biotechnologies has formed strategic partnerships with leading biopharmaceutical companies. For instance, it collaborates with Genentech on T-cell receptor (TCR) based therapeutic products, providing a neoantigen-specific T-cell receptor identified using Adaptive's TCR discovery platform. The company also signed a multi-year collaboration with BeiGene to use clonoSEQ technology in developing novel therapies for lymphoid malignancies.
In terms of financial achievements, for the year ended December 31, 2023, Adaptive reported a total revenue of $170.3 million, with the MRD revenue contributing significantly to this growth. The company achieved substantial progress in clonoSEQ test volume and introduced strategic updates to maximize the value of its MRD and Immune Medicine businesses.
Adaptive Biotechnologies operates from biotech hubs in Seattle, Washington, and South San Francisco, California. Their team of world-class scientists and open, collaborative culture drive continuous innovation. The company's clinical diagnostics and pipeline developments aim to transform the clinical landscape, offering new hope for treating cancers, autoimmune disorders, and infectious diseases.
Recently, Adaptive Biotechnologies announced significant progress and strategic decisions to enhance its business operations. They integrated clonoSEQ into Epic’s specialty diagnostics suite, easing MRD monitoring accessibility for healthcare providers. The company continues to focus on driving operational efficiencies, as reflected by a decrease in operating expenses while maintaining sustainable growth.
Adaptive Biotechnologies remains committed to leveraging the adaptive immune system's potent capabilities to develop and commercialize immune-driven clinical products tailored to individual patient needs. With a robust cash position, Adaptive aims for profitability in its MRD business while making targeted investments in Immune Medicine.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) has announced that it will report its financial results for the fourth quarter and full year 2021 on February 15, 2022, following market close. The company will hold a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. A live audio webcast will be available on its website, with a replay accessible within 24 hours post-event.
Adaptive is focused on the adaptive immune system, developing diagnostic and therapeutic products. They have three commercial products and a strong clinical pipeline aimed at various diseases.
Adaptive Biotechnologies (ADPT) announced preliminary revenue for 2021, estimating it between $153 million and $154 million, a significant increase of approximately 56% from $98.4 million in 2020. CEO Chad Robins cited strong performance and positioned the company for sustainable growth in immune medicine and minimal residual disease (MRD) sectors. Additionally, CFO Chad Cohen will resign effective February 15, 2022, with principal accounting officer Kyle Piskel stepping in as interim CFO. Full financial results are set to be released around February 15, 2022.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 10:30 a.m. PT / 1:30 p.m. ET. This updated presentation time reflects a change from previous announcements. Interested parties can access a live and archived webcast of the presentation on the company’s website under the 'Investors' section. The company focuses on harnessing the adaptive immune system for clinical products aimed at diagnosing and treating diseases, with three commercial products and a robust clinical pipeline.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10th, 2022, at 12:45 p.m. PT / 3:45 p.m. ET. The company aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat diseases. Interested parties can access a live and archived webcast on the company’s website. Adaptive Biotechnologies focuses on developing immune-driven clinical products, with three commercial offerings and a robust pipeline addressing cancer, autoimmune conditions, and infectious diseases.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced promising data at the ASH 63rd Annual Meeting regarding its clonoSEQ Assay's ability to assess minimal residual disease (MRD) in multiple myeloma and chronic lymphocytic leukemia patients. Key findings from the MASTER trial showed that 71% of patients achieved two consecutive MRD-negative results, allowing for successful treatment discontinuation. The data supports clonoSEQ as a standard care tool, demonstrating its significance in monitoring blood cancers and potentially improving patient quality of life.
Adaptive Biotechnologies (Nasdaq: ADPT) will present over 30 abstracts at the 63rd Annual Meeting of the American Society of Hematology (ASH) from December 11-14, showcasing the effectiveness of its clonoSEQ® Assay for assessing minimal residual disease (MRD) in blood cancer patients. This FDA-approved assay is significant for conditions like multiple myeloma and chronic lymphocytic leukemia. The data highlights clonoSEQ's role in guiding treatment decisions, aiding in precise disease monitoring, and improving patient outcomes. The event will feature several oral and poster presentations emphasizing these findings.
Adaptive Biotechnologies (Nasdaq: ADPT) announced that Palmetto GBA's Molecular Diagnostics Program has finalized a local coverage determination (LCD) for the clonoSEQ® assay, which detects and monitors minimal residual disease (MRD) in blood cancers. This LCD includes coverage for B-cell acute lymphoblastic leukemia, multiple myeloma, and chronic lymphocytic leukemia, thereby expanding access for approximately 700,000 patients in the U.S. The clonoSEQ assay is the only FDA-cleared test for MRD assessment in these conditions and is currently available to over 240 million covered lives.
Adaptive Biotechnologies (ADPT) reported strong financial results for Q3 2021, with revenue of $39.5 million, a 50% increase year-over-year. Sequencing revenue saw a remarkable 96% growth, reaching $22.1 million. However, the company faced rising operating expenses of $95.8 million, leading to a net loss of $56.0 million, up from $36.7 million in Q3 2020. They reaffirmed their full-year revenue guidance of $148 million to $155 million, indicating a projected 54% growth compared to 2020. Cash reserves stood at $632.4 million as of September 30, 2021.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) will release its third quarter 2021 financial results on November 3, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. The event will be accessible via a live webcast on the company's website, with an archived replay available within 24 hours.
Adaptive focuses on leveraging the adaptive immune system for clinical products aimed at diagnosing and treating various diseases, including cancer and autoimmune conditions.
Adaptive Biotechnologies presented significant findings at IDWeek 2021 regarding its T-Detect™ COVID test, which can identify previous SARS-CoV-2 infections up to 12 months post-diagnosis. The test also distinguishes between natural infections and vaccine responses, outperforming traditional antibody tests. Additionally, results highlight that TCR repertoire characterization is nearly twice as sensitive as standard tests for identifying Lyme disease. These advancements illustrate the potential for T-cell testing to enhance clinical diagnostics and disease monitoring.
FAQ
What is the current stock price of Adaptive Biotechnologies Corporation (ADPT)?
What is the market cap of Adaptive Biotechnologies Corporation (ADPT)?
What is Adaptive Biotechnologies Corporation known for?
What is clonoSEQ?
Who are some of Adaptive Biotechnologies' key partners?
What were Adaptive Biotechnologies' financial highlights for 2023?
How does Adaptive Biotechnologies contribute to personalized medicine?
What recent strategic decisions has Adaptive Biotechnologies made?
Where are Adaptive Biotechnologies' main operations located?
What is the company culture at Adaptive Biotechnologies?
What are some key clinical applications of clonoSEQ?